Bone metastasis of prostate cancer combined treatment

The incidence of prostate cancer in men in the United States ranked first, second only to lung cancer for the second cancer cause of death. In our country, along with changes in the structure of people's diet and the extension of average life expectancy in recent years, the incidence of prostate cancer has been an upward trend. Because the symptoms of prostate cancer similar to benign prostatic hyperplasia, the incidence of occult, and its symptoms are often ignored, when the time of diagnosis, about 7 0% have local invasion or distant metastasis (including bone metastases). Prostate cancer bone metastases is the most common symptom of bone metastases in different parts of the degree of pain, clinically effective treatment for their little. Clinical diagnosis of prostate cancer is usually a clear implementation of castration and anti-androgen treatment, bone metastases secondary to multiple sites of pain associated with lesions of the cases, the use of continuing to take anti-androgen drugs at the same time, with sr treatment of radionuclide (irradiation) and some lesions radiation therapy (external beam radiotherapy) combined with surgical treatment of the combination therapy.

Anti-androgen therapy in the early stages of androgen receptor-positive cancer cells due to the lack of androgen stimulation and apoptosis, tumor volume can be gradually reduced; with treatment, and partial androgen receptor-positive cells gradually differentiated into a hung hormone receptor-negative cells. At this point, the anti-androgen therapy decreased the effects of the emergence of difficult to control the primary lesion of prostate cancer and bone metastases development in patients with this part, we continue to take anti-androgen drugs, based on the use of radionuclides increases sr with radiation therapy for bone metastases larger lesions of bone metastases with external radiation therapy combined with surgical treatment of the combination therapy. sr is a bone metastasis of radionuclides, it is the main use of its launch of pure B-ray (half-life of 5 0. 5 d) for bone tumors with radiation therapy, intravenous injection into the human body the main concentration in the bone metastases osteoclastic foci or areas of osteoblast response to launch anti-cancer radiotherapy to reduce the disease and even disappear, so as to achieve the purpose of pain, and normal bone tissue to absorb very little sr. After the application of sr, bone metastases have a temporary local hyperemia, edema response to increased pressure on local nerves, so that some patients a temporary increase of bone pain, pain that is blinking phenomenon, generally 3 ~ 5d to be local reactions after sr subsided and after treatment appear gradually, the pain began to reduce, or even disappear. Bone metastasis of prostate cancer as a result of a number of regular positions, extensive transfer, the application of radiotherapy is limited, and the radionuclide can be achieved within the radiation therapy treatment at the same time more than the effect of lesions and satisfactory; but a one or 2 large transfer of weight-bearing bone lesions, radiation therapy nuclides would be difficult to achieve the desired results, so when supplemented by external radiation therapy can make up for its shortcomings.

Reported in the literature abroad for prostate cancer pain caused by bone metastases, sr inside and outside the radiation therapy radiotherapy for pain relief rates were 80% and 68%.